10 results about "Mouse Leukemia" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to application of small peptide PEARL in diagnosis and targeted therapy of acute myelogenous leukemia. When leukemia patient samples and leukemia cell lines are detected, obvious low expression of the small peptide PEARL in acute myelogenous leukemia patients is found. Meanwhile, the research finds that PROSER2-AS1 does not play a role, but plays a role through the coded small peptide PEARL. A mouse leukemia model experiment further finds that the overexpressed small peptide PEARL can significantly inhibit the survival of acute myelogenous leukemia cells and significantly prolong the life cycle of a model mouse. Finally, through mechanism research, it is found that the endoplasmic reticulum pressure of acute myelogenous leukemia cells is remarkably increased through overexpression of PEARL, the UPR reaction is activated, and therefore the functions of the acute myelogenous leukemia cells are affected. Therefore, the invention can provide a new accurate judgment or treatment strategy for diagnosis or targeted treatment of acute myelogenous leukemia.

The invention provides an anti-leukemia pharmaceutical composition based on DNA damage activated NKT cells and application of the anti-leukemia pharmaceutical composition. A mouse leukemia model is adopted as a research object, and experimental results show that in a C1498 homotransplantation tumor C57BL / 6 immune sound mouse leukemia model, the tumor inhibition rate of a daunorubicin and alpha-galactosylceramide combined treatment group reaches 67.4%, the survival time is remarkably prolonged, and obvious toxicity is not caused; in a C57 mouse leukemia model constructed by caudal vein injection of C1498, daunorubicin and alpha-galactosylceramide are combined to treat and reverse leukemia-related hepatosplenomegaly (the weight of liver and spleen is equivalent to that of a normal group), leukocyte proliferation is inhibited, and the survival state of mice is improved. The invention provides a new direction for treatment of leukemia.

The application discloses application of VK4 in preparation of a drug for treating leukemia, and belongs to the leukemia treatment field. The application research finds that VK4 can inhibit proliferation of leukemia cells through cycle arrest and induction of apoptosis, and VK4 can inhibit proliferation of HL60 cells and K562 cells through blocking of a JAK / STAT signal path. The results of Wright's staining, immunohistochemical staining and H&E staining of a mouse leukemia model show that VK4 also has an anti-leukemia effect in vivo, and has no obvious liver and kidney damage, and can provide a new drug selection for clinical treatment of leukemia.

The invention belongs to the technical field of biological medicine, and particularly relates to application of RNA binding protein RBM15B in MLL fusion gene leukemia (MLL-R). A large number of leukemia patient samples are detected through the qRT-PCR technology, it is found that RBM15B in MLL fusion leukemia patients is remarkably and highly expressed, and the highly expressed RBM15B is remarkably and negatively correlated with the survival rate of the patients; furthermore, a mouse leukemia model is constructed through a mouse MLL-AF9 cell source and a human MLL fusion leukemia cell line for adult level verification, and it is found that the survival of MLL fusion gene leukemia cells can be remarkably inhibited by knocking down the expression of RBM15B, and the life cycle of a model mouse is remarkably prolonged. The result shows that RBM15B is expected to be used as a diagnostic marker and / or a therapeutic target to play a role in MLL fusion leukemia.

This invention belongs to the field of biomedical technology, specifically relating to the application of the RNA-binding protein RBM15B in MLL fusion gene leukemia (MLL-R). Using qRT-PCR technology, this invention detected significant high expression of RBM15B in a large number of leukemia patient samples, revealing a significant negative correlation between high RBM15B expression and patient survival rate. Further validation at the adult level was achieved by constructing mouse leukemia models using mouse MLL-AF9 cells and human MLL fusion gene leukemia cell lines. The results showed that knocking down RBM15B expression significantly inhibited the survival of MLL fusion gene leukemia cells and significantly prolonged the lifespan of the model mice. This indicates that RBM15B holds promise as a diagnostic marker and / or therapeutic target in MLL fusion gene leukemia.

The invention discloses application of VK4 in preparation of drugs for treating leukemia, and belongs to the field of leukemia treatment. The research finds that VK4 can inhibit leukemia cell proliferation through cycle arrest and apoptosis induction, and the VK4 can inhibit proliferation of HL60 cells and K562 cells through blocking a JAK / STAT signal channel. A mouse leukemia model is subjected to Wright staining, immunohistochemistry and Hamp; e staining results show that the VK4 also has an anti-leukemia effect in vivo, has no obvious liver and kidney injury, and can provide a new drug choice for clinical treatment of leukemia.

The application belongs to the technical field of biological medicine, and particularly relates to application of a small peptide PEARL in diagnosis and targeted treatment of acute myeloid leukemia. The application detects samples of leukemia patients and leukemia cell lines, and finds that the small peptide PEARL is significantly lowly expressed in patients with acute myeloid leukemia. Meanwhile, it is found through research that PROSER2-AS1 does not play a role by itself, but plays a function through the coded small peptide PEARL. Further through a mouse leukemia model experiment, it is found that overexpression of the small peptide PEARL can significantly inhibit survival of acute myeloid leukemia cells, and significantly prolong the survival cycle of model mice. Finally, through mechanism research, it is found that overexpression of PEARL significantly increases endoplasmic reticulum stress of acute myeloid leukemia cells, activates UPR response, and thus affects functions of the acute myeloid leukemia cells. Therefore, the application can provide a new precise judgment or treatment strategy for diagnosis or targeted treatment of acute myeloid leukemia.

The application provides a method for constructing 1,2-cis fucose glycoside bond with high stereoselectivity and application in preparation of 13-sugar repeating units and 9-sugar substructures of angelica polysaccharide APS-1II, and evaluation of anti-leukemia activity of the 13-sugar and 9-sugar, and belongs to the technical field of polysaccharide preparation; the application realizes a promoter composition of 1,2-cis fucose glycosylation reaction with high stereoselectivity, which comprises iodotrimethylsilane (TMSI) and triphenyl phosphine oxide (Ph3PO), and the donor is fucosyl N-phenyl trifluoroacetyl imidate (PTFAI) with acyl substitution at O-3 and / or O-4 positions. The 13-sugar repeating units and 9-sugar substructures of angelica polysaccharide APS-1II provided by the application have significant inhibitory effect on human leukemia K562 cells and mouse leukemia L1210 cells.

The invention provides a method for constructing a 1, 2-cis fucose glycosidic bond with high stereoselectivity and application of the method to preparation of a 13 sugar repeating unit and a substructure 9 sugar of angelica polysaccharide APS-1II and evaluation of anti-leukemia activity of the 13 sugar and the 9 sugar, and belongs to the technical field of polysaccharide preparation. The accelerant composition for realizing the high-stereoselectivity 1, 2-cis-fucose glycosylation reaction comprises trimethylsilyl iodide (TMSI) and triphenylphosphine oxide (Ph3PO), and fucosyl N-phenyl trifluoroacetyl imine ester (PTFAI) of which the O-3 position and / or the O-4 position are / is substituted by acyl is used as a donor. The 13 sugar repeating unit of the angelica polysaccharide APS-1II and the substructure 9 sugar thereof provided by the invention have a remarkable inhibition effect on the activity of human leukemia K562 cells and mouse leukemia L1210 cells.

The application belongs to the technical field of biological medicine, and particularly relates to application of circular RNA (circRNA) CIRC8341 in leukemia. The application proves that the circular RNA CIRC8341 is stably present in leukemia cells and is generally highly expressed in leukemia cell lines through RNase R experiments and qRT-PCR experiments. Meanwhile, it is found through research that targeting CIRC8341 can significantly inhibit the growth of leukemia cells; the test results of a mouse leukemia model show that knocking down the expression of CIRC8341 can significantly inhibit the survival of leukemia cells and significantly prolong the survival cycle of model mice. The above results show that CIRC8341 can play a role in leukemia as a therapeutic target.